The rollout of COVID-19 vaccines has been slower and more difficult than Americans had hoped, plagued by an undersupply that the Biden administration is trying to overcome. The new administration announced on Feb. 11 that it had finalized a deal to buy 200 million more doses of the Pfizer BioNTech and Moderna versions of the vaccine, the first to receive…